Ompenaclid (Standard)

Ompenaclid (RGX-202) is an oral small-molecule SLC6A8 transporter inhibitor. Ompenaclid robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis. Ompenaclid can be used for the research of cancer and duchenne muscular dystrophy[1][2].

Product Specifications

CAS Number

[353-09-3]

UNSPSC

12352211

Target

Apoptosis; Endogenous Metabolite

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Field of Research

Cancer

Smiles

O=C(O)CCNC(N)=N

Molecular Formula

C4H9N3O2

Molecular Weight

131.14

References & Citations

[1]Kurth I, et al. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Sci Adv. 2021 Oct 8;7 (41) :eabi7511.|[2]Creisméas A, et, al. TRPC1 and TRPC3 involvement in DMD physiopathology and as potential targets for treatment in complement to rAAV-microdystrophin. 2021 Oct 1;13.